Researchers have uncovered a novel pathway that explains how cancer cells become resistant to chemotherapies, which in turn offers a potential solution for preventing chemo-resistance.
Sep 20, 2022
0
43
While chemotherapy drugs can be lifesaving, they don't work for all patients or for all cancers. But a team of UTM researchers is looking at new ways to use special types of light to target cancer cells resistant to current ...
Sep 14, 2022
0
85
Up to three quarters of patients receiving cancer chemotherapy suffer from "chemo brain"—a long-term side effect that makes it harder to remember things, maintain attention, and learn new information. When it strikes children, ...
Sep 13, 2022
0
565
Though chemotherapy can be lifesaving, the cancer treatment often leaves patients suffering from debilitating side effects, including cognitive impairments in processing speed, memory, executive function and attention. Dubbed ...
Sep 2, 2022
0
81
An experimental combination of two drugs halts the progression of small cell lung cancer, the deadliest form of lung cancer, according to a study in mice from researchers at Washington University School of Medicine in St. ...
Aug 31, 2022
0
115
Clonal hematopoiesis is a biological process in which a blood stem cell (the population that gives rise to a variety of blood cell types) acquires an advantageous mutation and outgrows neighboring cells. Clonal hematopoiesis ...
Aug 2, 2022
0
23
Two of the most common genetic changes that cause cells to become cancerous, which were previously thought to be separate and regulated by different cellular signals, are working in concert, according to new research from ...
Jul 7, 2022
0
99
Approximately 1 in 25 people will develop colon cancer during their lifetime and nearly 2 million cases new cases are diagnosed worldwide each year. Chemotherapy is commonly used to treat colon cancer. While this treatment ...
Jul 1, 2022
0
1896
A group of drugs commonly used to treat erectile dysfunction may be able to boost the effect of chemotherapy in esophageal cancer, according to new research.
Jun 21, 2022
0
137
In a prospective phase II study that involved patients with mismatch repair–deficient locally advanced rectal cancer, treatment with neoadjuvant single-agent, PD1 inhibitor dostarlimab resulted in a clinical complete response—as ...
Jun 9, 2022
0
72
